Searchable abstracts of presentations at key conferences in endocrinology

ea0099ep281 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024

Fluasterone buccal tablets: a promising therapy for the metabolic effects of hypercortisolemia and cushing syndrome

Vrachnis Dionysios , Efstathiadou Zoi , Goulis Dimitrios , Kassi Eva , Lymniati Christina , Ntali Georgia , Peppa Melpomeni , Stavrinos Konstantinos , Vryonidou Andromahi , Xekouki Paraskevi , Stratakis Constantine

Fluasterone (16-α-fluoro-5-androsten-17-one) is a structural analogue of dehydroepiandrosterone (DHEA) that retains DHEA clinical properties without its androgenic effects. In animal models, fluasterone exhibits DHEA-like effects, including anti-inflammatory, anti-proliferative, and anti-diabetic properties but is consistently more potent than DHEA. An orphan-drug designation for fluasterone has been granted by the FDA for treatment of Cushing’s syndrome (CS), includ...